DNA　methylation　abnormalities　are　frequent　events　in　early　tumors.　Additionally,　DNA　methylation　is　relatively　stable　over　time　and　can　be　non-invasively　detected　in　blood.　Therefore,　DNA　methylation　has　a　great　potential　to　become　an　early　diagnostic　biomarker　of　cancers.　In　order　to　find　potential　diagnostic　markers　for　lung　squamous　cell　carcinoma　(LUSC),　a　method　for　identifying　LUSC-specific　candidate　diagnostic　markers　was　proposed.　We　screened　6　LUSC-specific　CpGs　by　comparing　the　methylation　profiles　of　172　samples　from　LUSC　patients,　42　normal　lung　samples,　184　normal　blood　samples,　and　1　306　samples　from　patients　with　other　cancers　which　was　collected　from　TCGA　(The　Cancer　GenomeAtlas)　database.　A　supportvector　machine　model　was　constructed　to　distinguish　LUSC　patients　from　normal　controls.　The　combination　of　six　sites　achieved　93%-99%　sensitivity　in　predicting　LUSC,　100%　specificity　in　excluding　all　normal　samples,　and　similar　to　99%　specificity　in　excluding　other　cancers.　Overall,　our　study　provides　promising　biomarkers　for　the　diagnosis　of　LUSC.